Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia

In 48 week open-label treatment period of phase 2 trial (n=96; LDL-C 3.77 mmol/L.), evinacumab (15mg/kg IV every 4 weeks) provided sustained reductions in LDL-C over time, with a mean reduction of 45.5% at week 72 from baseline.

SPS commentary:

Angiopoietinlike protein 3 (ANGPTL3) plays an important role in regulating lipoprotein metabolism via inhibition of lipoprotein lipase and endothelial lipase. Evinacumab is a monoclonal antibody that inhibits ANGPTL3, promoting remodeling of very low-density lipoprotein and leading to reduced LDL-C levels. It is licensed in UK as an adjunct to diet and other LDL-C lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia.

JAMA Cardiology